Deepening Understanding of Early, Translational and Late Stage Clinical Science to Support NASH Candidate Entry to Market
At the world’s premiere NASH Summit, Dr. Morten Asser Karsdal, CEO of Nordic Bioscience will explain how collagen biomarkers can be used to identify patients with high disease activity and who are therefore more prone to fibrosis progression, and how they can distinguish between liver and cardiovascular events.
Tune in on December 1 at 11:00 am EST to learn more about the organ death race!
